pharma · Gram-negative Bacterial Infections · SARS-CoV-2 Infection
Shionogi Inc. (U.S.)
Shionogi B.V.
NovaPharmaNews editorial coverage mentioning Shionogi Inc. (U.S.) — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Florham Park, USA
- Founded
- 2001
- Employees
- 601
- Programs
- 6
- Drugs
- 8
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Shionogi Inc. (U.S.) — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Shionogi Inc. (U.S.) — regulatory, clinical, and market analysis.
FDA Approves Xocova: A Catalyst for Pharmaceutical M&A and Licensing
The FDA has approved Shionogi's Xocova, marking a significant development in COVID-19 prevention. This approval coincides with a surge in pharmaceutical industry mergers and licensing deals, signaling a dynamic period for the sector.
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
Structured plan for FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
Shionogi's Xocova Gains FDA Clearance for COVID-19 Post-Exposure Prevention
Shionogi's COVID-19 antiviral, Xocova, has secured FDA approval for use as a post-exposure preventative measure. This clearance expands the therapeutic landscape for managing SARS-CoV-2 infections.